Insider Selling: Emergent Biosolutions (NYSE:EBS) SVP Sells 3,000 Shares of Stock

Emergent Biosolutions Inc. (NYSE:EBS) SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares in the company, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Trading Down 1.4%

EBS traded down $0.12 during trading hours on Thursday, reaching $8.16. 335,640 shares of the company’s stock traded hands, compared to its average volume of 880,742. The firm has a 50-day moving average price of $8.36 and a 200 day moving average price of $9.67. The firm has a market capitalization of $421.11 million, a PE ratio of -29.12 and a beta of 2.34. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10. Emergent Biosolutions Inc. has a 52-week low of $5.61 and a 52-week high of $14.06.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.46. The business had revenue of $156.10 million during the quarter, compared to the consensus estimate of $145.00 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

Analyst Ratings Changes

A number of brokerages have commented on EBS. HC Wainwright reduced their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a report on Monday, March 9th. Wall Street Zen downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Weiss Ratings cut shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $12.00.

Hedge Funds Weigh In On Emergent Biosolutions

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in Emergent Biosolutions during the 4th quarter valued at about $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Emergent Biosolutions in the fourth quarter valued at approximately $45,000. Legal & General Group Plc purchased a new position in Emergent Biosolutions during the second quarter worth approximately $31,000. Farther Finance Advisors LLC boosted its stake in Emergent Biosolutions by 361.3% during the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 4,827 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Emergent Biosolutions during the second quarter worth $53,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.